Mixtures of wild-type and a pathogenic (E22G) form of Aβ40 in vitro accumulate protofibrils, including amyloid pores

Journal of Molecular Biology

Volumn 332, Issue 4, 2003, Pages 795-808

  Lashuel, Hilal A ^a,b   Hartley, Dean M ^a,b   Petre, Benjamin M ^b   Wall, Joseph S ^c   Simon, Martha N ^c   Walz, Thomas ^a,b   Lansbury Jr , Peter T ^a,b  

^a The Harvard Center for Neurodegeneration & Repair   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Alzheimer's disease; Amyloid pores; Amyloid protein (A ); Arctic mutation; Protofibrils

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ELECTRON MICROSCOPY; FIBER; HETEROZYGOSITY; HUMAN; IN VITRO STUDY; MORPHOLOGY; MUTATION; OLIGOMERIZATION; PRIORITY JOURNAL; WILD TYPE;

EID: 0041825430     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(03)00927-6     Document Type: Article

References (64)

1. Selkoe D.J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 275:1997;630-631.
2. Castano E.M., Frangione B. Biology of disease human amyloidosis, Alzheimer disease and related disorders. Lab. Invest. 58:1988;122-132.
3. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N.Y. Acad. Sci. 924:2000;17-25.
4. Wang R., Sweeney D., Gandy S.E., Sisodia S.S. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J. Biol. Chem. 271:1996;31894-31902.
5. Janus C., Phinney A.L., Chishti M.A., Westaway D. New developments in animal models of Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 1:2001;451-457.
6. Lichtenthaler S.F., Ida N., Multhaup G., Masters C.L., Beyreuther K. Mutations in the transmembrane domain of APP altering gamma-secretase specificity. Biochemistry. 36:1997;15396-15403.
7. Goldberg M.S., Lansbury P.T. Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nature Cell Biol. 2:2000;E115-E119.
8. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad Sci. USA. 95:1998;6448-6453.
9. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4:1997;119-125.
10. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., Teplow D.B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272:1997;22364-22372.
11. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274:1999;25945-25952.
12. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Jr. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 38:1999;8972-8980.
13. Lemere C.A., Blusztajn J.K., Yamaguchi H., Wisniewski T., Saido T.C., Selkoe D.J. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3:1996;16-32.
14. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. J. Am. Med. Assoc. 283:2000;1571-1577.
15. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46:1999;860-866.
16. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad Sci. USA. 96:1999;3228-3233.
17. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274:1999;6483-6492.
18. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19:1999;8876-8884.
19. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511.
20. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539.
21. Aksenova M.V., Aksenov M.Y., Butterfield D.A., Carney J.M. alpha-1-antichymotrypsin interaction with A beta (1-40) inhibits fibril formation but does not affect the peptide toxicity. Neurosci. Letters. 211:1996;45-48.
22. Stege G.J., Renkawek K., Overkamp P.S., Verschuure P., van Rijk A.F., Reijnen-Aalbers A., et al. The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. Biochem. Biophys. Res. Commun. 262:1999;152-156.
23. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., et al. The "Arctic" APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nature Neurosci. 4:2001;887-893.
24. Hardy J. The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc. Natl Acad Sci. USA. 94:1997;2095-2097.
25. Lannfelt L., Nordstedt C. Genetics of Alzheimer's disease - routes to the pathophysiology. J. Neural. Transm. Suppl. 59:2000;155-161.
26. Haass C., Steiner H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nature Neurosci. 4:2001;859-860.
27. Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 418:2002;291.
28. Ding T.T., Lee S.J., Rochet J.C., Lansbury P.T. Jr. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry. 41:2002;10209-10217.
29. Huang T.H., Yang D.S., Plaskos N.P., Go S., Yip C.M., Fraser P.E., Chakrabartty A. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J. Mol. Biol. 297:2000;73-87.
30. Lashuel H., Petre B., Wall J., Simon M., Nowak R., Walz T., Lansbury P. alpha-Synuclein especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322:2002;1089-1102.
31. Valeva A., Schnabel R., Walev I., Boukhallouk F., Bhakdi S., Palmer M. Membrane insertion of the heptameric staphylococcal alpha-toxin pore. A domino-like structural transition that is allosterically modulated by the target cell membrane. J. Biol. Chem. 276:2001;14835-14841.
32. Haass C., Baumeister R. What do we learn from a few familial Alzheimer's disease cases? J. Neural. Transm. Suppl. 54:1998;137-145.
33. Van Nostrand W.E., Melchor J.P., Cho H.S., Greenberg S.M., Rebeck G.W. Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J. Biol. Chem. 276:2001;32860-32866.
34. Walsh D.M., Hartley D.M., Condron M.M., Selkoe D.J., Teplow D.B. In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692→Gly) Alzheimer's disease. Biochem. J. 355:2001;869-877.
35. Chiti F., Calamai M., Taddei N., Stefani M., Ramponi G., Dobson C.M. Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc. Natl Acad. Sci. USA. 99:2002;16419-16426.
36. Massi F., Klimov D., Thirumalai D., Straub J.E. Charge states rather than propensity for beta-structure determine enhanced fibrillogenesis in wild-type Alzheimer's beta-amyloid peptide compared to E22Q Dutch mutant. Protein Sci. 11:2002;1639-1647.
37. Kirkitadze M.D., Condron M.M., Teplow D.B. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J. Mol. Biol. 312:2001;1103-1119.
38. Snyder S.W., Ladror U.S., Wade W.S., Wang G.T., Barrett L.W., Matayoshi E.D., et al. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67:1994;1216-1228.
39. Hasegawa K., Yamaguchi I., Omata S., Gejyo F., Naiki H. Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry. 38:1999;15514-15521.
40. Rochet J.C., Conway K.A., Lansbury P.T. Jr. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry. 39:2000;10619-10626.
41. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad Sci. USA. 97:2000;571-576.
42. Shtilerman M.D., Ding T.T., Lansbury P.T. Jr. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry. 41:2002;3855-3860.
43. Lee H.J., Lee S.J. Characterization of cytoplasmic alpha-synuclein aggregates: fibril formation is tightly linked to the inclusion forming process in cells. J. Biol. Chem. 277:2002;48976-48983.
44. Poirier M.A., Li H., Macosko J., Cai S., Amzel M., Ross C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277:2002;41032-41037.
45. El-Agnaf O.M., Nagala S., Patel B.P., Austen B.M. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J. Mol. Biol. 310:2001;157-168.
46. Lashuel H.A., Lai Z., Kelly J.W. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry. 37:1998;17851-17864.
47. Lashuel H.A., Wurth C., Woo L., Kelly J.W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry. 38:1999;13560-13573.
48. Sousa M.M., Cardoso I., Fernandes R., Guimaraes A., Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159:2001;1993-2000.
49. Wallace A.J., Stillman T.J., Atkins A., Jamieson S.J., Bullough P.A., Green J., Artymiuk P.J. E. coli hemolysin E (HlyE, ClyA, SheA): X-ray crystal structure of the toxin and observation of membrane pores by electron microscopy. Cell. 100:2000;265-276.
50. Hirakura Y., Lin M.C., Kagan B.L. Alzheimer amyloid abeta1-42 channels: effects of solvent, pH, and Congo Red. J. Neurosci. Res. 57:1999;458-466.
51. Anguiano M., Nowak R.J., Lansbury P.T. Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry. 41:2002;11338-11343.
52. Mirzabekov T.A., Lin M.C., Kagan B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271:1996;1988-1992.
53. Hirakura Y., Azimov R., Azimova R., Kagan B.L. Polyglutamine-induced ion channels: a possible mechanism for the neurotoxicity of Huntington and other CAG repeat diseases. J. Neurosci. Res. 60:2000;490-494.
54. Hirakura Y., Carreras I., Sipe J.D., Kagan B.L. Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense. Amyloid. 9:2002;13-23.
55. Hirakura Y., Kagan B.L. Pore formation by beta-2-microglobulin: a mechanism for the pathogenesis of dialysis associated amyloidosis. Amyloid. 8:2001;94-100.
56. Kourie J.I., Farrelly P.V., Henry C.L. Channel activity of deamidated isoforms of prion protein fragment 106-126 in planar lipid bilayers. J. Neurosci. Res. 66:2001;214-220.
57. Kourie J.I. Prion channel proteins and their role in vacuolation and neurodegenerative diseases. Eur. Biophys. J. 31:2002;409-416.
58. Volles M.J., Lansbury P.T. Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 41:2002;4595-4602.
59. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., Lansbury P.T. Jr. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 40:2001;7812-7819.
60. Kagan B.L., Hirakura Y., Azimov R., Azimova R., Lin M.C. The channel hypothesis of Alzheimer's disease: current status. Peptides. 23:2002;1311-1315.
61. Lansbury P.T. Jr, Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Genet. Dev. 12:2002;299-306.
62. Caughey B., Lansbury P. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from their innocent bystandards. Annu. Rev. Neurosci. 26:2003;267-298.
63. Frank J., Radermacher M., Penczek P., Zhu J., Li Y., Ladjadj M., Leith A. SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J. Struct. Biol. 116:1996;190-199.
64. Wall J.S., Simon M.N. Scanning transmission electron microscopy of DNA-protein complexes. Methods Mol. Biol. 148:2001;589-601.